Myovant Sciences Ltd (NASDAQ:MYOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “

Separately, Evercore ISI assumed coverage on shares of Myovant Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $18.20.

Shares of Myovant Sciences (MYOV) traded down 0.16% during trading on Thursday, reaching $12.37. The company had a trading volume of 22,218 shares. Myovant Sciences has a 52-week low of $9.92 and a 52-week high of $15.50. The company’s market capitalization is $752.64 million. The firm has a 50-day moving average price of $12.05 and a 200-day moving average price of $12.05.

TRADEMARK VIOLATION WARNING: “Myovant Sciences Ltd (MYOV) Lifted to “Hold” at Zacks Investment Research” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/10/myovant-sciences-ltd-myov-lifted-to-hold-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently bought and sold shares of MYOV. RA Capital Management LLC boosted its stake in shares of Myovant Sciences by 56.6% in the first quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock valued at $27,570,000 after purchasing an additional 848,422 shares during the period. Eventide Asset Management LLC purchased a new position in shares of Myovant Sciences in the first quarter valued at approximately $3,463,000. Emory University purchased a new position in shares of Myovant Sciences in the second quarter valued at approximately $1,512,000. BB Biotech AG boosted its stake in shares of Myovant Sciences by 3.4% in the first quarter. BB Biotech AG now owns 3,302,835 shares of the company’s stock valued at $38,775,000 after purchasing an additional 110,000 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in shares of Myovant Sciences in the second quarter valued at approximately $648,000.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.